Nanoviricides, Inc.

Organization and Nature of Business NanoViricides, Inc. (the Company , NanoViricides , we, or us ) was incorporated in Nevada on April 1, 2005, and redomiciled to Delaware effective May 30, 2023. Our corporate offices are located at 1 Controls Drive, Shelton, Connecticut 06484 and our telephone number is (203) 937-6137. Our Website is located at http://www.Nanoviricides.com . We do not incorporate by reference into this Annual Report the information on or accessible through our website, and you should not consider it part of this Annual Report. On September 25, 2013, the Company’s common stock began trading on the New York Stock Exchange American under the symbol, NNVC . We are a clinical stage company. Phase II clinical trials of our first drug, NV-387, has previously successfully completed a Phase Ia/Ib clinical trial for human clinical safety and tolerability, wherein the drug was found to be safe and well tolerated, with no reportable adverse events, and no subjects dropping out.. Additionally, drug candidates in various stages of pre-clinical development, including IND-filing stage and late stage IND-enabling non-clinical studies. We have no customers, products or revenues to date, and may never achieve revenues or profitable operations. We are engaged in developing a class of drugs, that we call nanoviricides , using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases.